<DOC>
	<DOCNO>NCT00003875</DOCNO>
	<brief_summary>This phase II trial study side effect well give busulfan etoposide follow peripheral blood stem cell transplant ( PBSCT ) low-dose aldesleukin work treat patient acute myeloid leukemia ( AML ) . Drugs use chemotherapy , busulfan etoposide , work different way stop growth cancer cell , either kill cell stop dividing . A PBSCT may able replace blood-forming cell destroy chemotherapy . This may allow chemotherapy give cancer cell kill . Aldesleukin may stimulate white blood cell kill cancer cell . Giving busulfan etoposide together follow PBSCT aldesleukin may effective treatment AML .</brief_summary>
	<brief_title>Busulfan Etoposide Followed Peripheral Blood Stem Cell Transplant Low-Dose Aldesleukin Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate toxicity overall survival high dose Bu ( busulfan ) /VP-16 ( etoposide ) follow post-transplant low-dose interleukin ( IL ) -2 ( aldesleukin ) patient AML . SECONDARY OBJECTIVES : I . To estimate rate relapse associate regimen . OUTLINE : PREPARATIVE REGIMEN : Patients receive busulfan intravenously ( IV ) 2 hour orally ( PO ) every 6 hour day -7 -4 etoposide IV day -3 . STEM CELL INFUSION : Patients undergo autologous syngeneic PBSC rescue day 0 . POST-TRANSPLANT ALDESLEUKIN THERAPY : Beginning 30-100 day transplant , patient receive low-dose aldesleukin subcutaneously ( SC ) daily 12 week . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>The patient must AML fall one follow category : AML 1st complete remission ( CR ) intermediate high risk relapse follow conventional therapy ; least , one follow feature need : Patient require one cycle induction achieve first CR White blood cell count ( WBC ) &gt; 100,000/mm^3 diagnosis Any follow cytogenetic abnormality : inv ( 3 ) , ( 3:3 ) , del ( 5q ) 5 , 11q23 , del ( 7q ) 7 , del ( 20q ) 20 , abnormal 12p , +11 t8 Any abnormality combination abnormality would predict intermediate high risk relapse AML beyond first CR Any patient identical twin donor also meet criteria Patients AML 1st CR receive least two cycle consolidation chemotherapy prior mobilization transplant Patients must adequate number stem cell previously collect ( i.e. , &gt; 2 x 10^8 total nucleate cell [ TNC ] bone marrow [ BM ] /kg 4 x 10^6 [ CD ] 34+ PBSC/kg , unless approve otherwise Dr. Holmberg ) ; prior stem cell collection patient must document remission receive two cycle consolidation therapy induction therapy PreStudy test perform Patient must sign institutional review board ( IRB ) approve informed consent , conform federal institutional guideline Patients good risk AML define cytogenetic evaluation abnormality : inversion 16 t8 ; 21 Patient 's life expectancy severely limited disease AML Patient human immunodeficiency virus ( HIV ) seropositive Patient pregnant Patient 's creatinine &gt; 2.0 mg/dl Patient 's total bilirubin &gt; 2.0 mg/dl ( unless Gilbert 's disease ) Or serum glutamic oxaloacetic transaminase ( SGOT ) /serum glutamic pyruvic transaminase ( SGPT ) &gt; = 2.5 x upper limit normal ( ULN ) due leukemia Patient history congestive heart failure , uncontrolled arrhythmia leave ventricular ejection fraction ( LVEF ) &lt; 50 % Patient unrelated human leukocyte antigen ( HLA ) match donor eligible high priority Fred Hutchinson Cancer Research Center ( FHCRC ) protocol ( FHCRC patient ) Patient HLA match one antigen mismatch family donor available Patients significant active infection precludes transplant Patients Karnofsky Performance Score less 70</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>